ArticleDementia and neurocognitive disorders2020
History of Coffee Consumption and Risk of Alzheimer's Disease: a Meta-epidemiological Study of Population-based Cohort Studies.
Article in Dementia and neurocognitive disorders, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 11 citations in OpenAlex.
- Alzheimer's disease prevention by flavonols and their analogs.The journal of prevention of Alzheimer's disease · 2026Review
- Review
- ACurrent medicinal chemistry · 2022Review
- Neuroprotective Effects of Coffee Bioactive Compounds: A Review.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
background and purposeFour published quantitative systematic reviews showed conflicting results involving coffee consumption and the risk of Alzheimer's disease (AD). The aim of this meta-epidemiological meta-analysis (MEMA) was to evaluate the factors underlying the conflicting results and estimate the effect size and direction of the AD risk associated with coffee consumption in population-based cohort studies.
methodsThe primary subjects of MEMA were derived from 3 cohort studies selected by the related systematic reviews. Additional studies involving the primary subjects were searched using citation discovery tools. Prospective cohort studies evaluating the association between coffee consumption and AD risk were selected. A fixed effects model was applied to estimate the summary relative risk (sRR) and its 95% confidence intervals (CIs). Subgroup analysis was conducted according to the level of coffee consumption. Egger's test was used to evaluate publication bias.
resultsFour cohort studies were finally selected. A total of 36,300 participants from Finland, Sweden, Germany, and the United States of America were selected. The sRR (and its 95% CI) (I-squared value) by highest-versus-lowest method was 0.98 (0.92-1.05) (0.0%). In addition, none of the results of subgroup analyses by the level of coffee consumption showed any statistical significance.
conclusionsThis MEMA found that there was no association between coffee consumption and AD risk. Based on recent evidence suggesting that gene-environment interactions contribute to AD pathogenesis, it is necessary to conduct population-based cohort studies involving non-Caucasians.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.